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ABSTRACT Staphylococcus aureus causes severe disease in humans for which no li-
censed vaccine exists. A novel S. aureus vaccine (SA4Ag) is in development, target-
ing the capsular polysaccharides (CPs) and two virulence-associated surface proteins.
Vaccine-elicited antibody responses to CPs are efﬁcacious against serious infection
by other encapsulated bacteria. Studies of natural S. aureus infection have also
shown a role for TH17 and/or TH1 responses in protection. Single-antigen vaccines,
including CPs, have not been effective against S. aureus; a multiantigen vaccine ap-
proach is likely required. However, the impact of addition of protein antigens on the
immune response to CPs has not been studied. Here, the immune response induced
by a bivalent CP conjugate vaccine (to model the established mechanism of action
of vaccine-induced protection against Gram-positive pathogens) was compared to
the response induced by SA4Ag, which contains both CP conjugates and protein an-
tigens, in cynomolgus macaques. Microengraving, ﬂow cytometry, opsonophagocytic
assays, and Luminex technology were used to analyze the B-cell, T-cell, functional
antibody, and innate immune responses. Both the bivalent CP vaccine and SA4Ag
induced cytokine production from naive cells and antigen-speciﬁc memory B-cell
and functional antibody responses. Increases in levels of circulating, activated T cells
were not apparent following vaccination, nor was a TH17 or TH1 response evident.
However, our data are consistent with a vaccine-induced recruitment of T follicular
helper (TFH) cells to lymph nodes. Collectively, these data suggest that the response
to SA4Ag is primarily mediated by B cells and antibodies that abrogate important
S. aureus virulence mechanisms.
IMPORTANCE Staphylococcus aureus causes severe disease in humans for which no
licensed vaccine exists. A novel vaccine is in development that targets multiple ele-
ments of the bacteria since single-component vaccines have not shown efﬁcacy to
date. How these multiple components alter the immune response raised by the vac-
cine is not well studied. We found that the addition of two protein components did
not alter substantially the antibody responses raised with respect to function or mo-
bilization of B cells. There was also not a substantial change in the activity of T cells,
another part of the adaptive response. This study showed that protection by this
vaccine may be mediated primarily by antibody protection.
KEYWORDS immunization, memory B cells, microengraving
The Gram-positive bacterium Staphylococcus aureus is a pathogen of major impor-tance to public health. While S. aureus commonly asymptomatically colonizes the
skin and nose of healthy humans, severe disease can result from infection of the blood,
bone, skin, and lungs, as well as sites of catheters and prosthetic material (1). The threat
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posed by S. aureus is further exacerbated by the development of strains resistant to
methicillin (methicillin-resistant S. aureus [MRSA] strains) and other antibiotics that
are estimated to have caused more than 75,000 infections and over 9,600 deaths in the
United States in 2012 (2). Since there are currently no licensed vaccines against
S. aureus infection, novel therapeutics to treat or prevent this disease are urgently
needed.
To develop a vaccine against S. aureus, efforts have focused on identifying the
mechanisms by which hosts resist this infection. Since S. aureus largely persists extra-
cellularly, it is not surprising that in vitro studies, animal models, and the susceptibili-
ties of patients with speciﬁc immunodeﬁciencies have collectively suggested that
neutrophil-based killing is critical for controlling S. aureus infection. TH17 cells promote
the recruitment and activation of neutrophils, which phagocytose and kill the bacteria;
TH17 responses have been implicated in protection against cutaneous S. aureus infec-
tions (3–10). This phagocytic killing can result from direct recognition of the bacteria
through innate receptors or antibody (Ab)-mediated phagocytosis (11–15). The role of
antibodies in immunity to S. aureus also implies a role for T follicular helper (TFH) cells;
this subset of T cells is essential for germinal center reactions and antibody afﬁnity
maturation and therefore controls the maturation of B cells and antibody production by
plasma cells (16). Additionally, the idea of a potential role for TH1 immune responses is
supported by the ability of S. aureus to persist intracellularly and by the observation
that gamma interferon (IFN-) can activate neutrophil killing mechanisms (5, 17–20).
Together, those studies demonstrated the role for adaptive immune responses in
resistance to S. aureus and identiﬁed speciﬁc components of the immune system that
may be useful to target with vaccination.
The identiﬁcation of speciﬁc molecular antigens of S. aureus that the immune system
can recognize has been another challenge for vaccine development (21–23). Like many
bacterial pathogens, S. aureus can evade detection by innate immune receptors by
encapsulating itself with polysaccharides (15, 24). Capsular polysaccharides (CPs) have
been well established as effective targets for vaccines against encapsulated bacteria,
such as Streptococcus pneumoniae, Haemophilus inﬂuenzae, and Neisseria meningitidis.
As many as eight capsular serotypes have been identiﬁed in S. aureus, but the majority
of disease-causing isolates express either capsular polysaccharide 5 (CP5) or CP8,
making these attractive vaccine targets (25). Expression of capsular polysaccharides,
however, can be dynamic during infection, and targeting additional protein antigens
may be necessary for adequate protection (26). Two S. aureus surface proteins that have
been identiﬁed as major virulence factors may serve as additional vaccine targets:
manganese transport protein C (MntC) and clumping factor A (ClfA). MntC is involved
in the scavenging of manganese ions, which are important both as nutrients for
S. aureus and as cofactors for superoxide dismutase, which enables S. aureus survival of
the neutrophil respiratory burst. ClfA promotes binding of S. aureus to platelets and
ﬁbrogen, which is necessary for disease pathogenesis in several models of infection
with this pathogen (27–33). Preclinical studies have demonstrated the ability of these
antigens to induce protection in animal models (32, 34–36). ClfA and MntC may
therefore serve as valuable antigens to combine with capsular polysaccharide conju-
gates in a vaccine against S. aureus.
The identiﬁcation of these antigens has led to the development of several candidate
vaccines at various stages of development (21–23). Use of a bivalent vaccine containing
the CP5 and CP8 polysaccharides conjugated to recombinant Pseudomonas aeruginosa
exoprotein A showed reduced bacteremia in initial phase III clinical trials (37). However,
a signiﬁcant protective effect was not observed in a subsequent trial (38), which may
have been due to the population chosen, suboptimal conjugate production, or differ-
ences in conjugate manufacture between trials (38). On the basis of the partial success
of this trial and strong preclinical evidence for the use of capsular polysaccharide
conjugates as vaccine candidates, a novel tetravalent vaccine (SA4Ag) has been de-
signed that includes CP5 and CP8, each conjugated to cross-reacting material 197
(CRM197), in addition to the MntC and ClfA antigens. The effect that the addition of
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these protein antigens may have on the anti-CP immune response has not been
studied in detail and is a topic of this publication.
To determine how the response to SA4Ag compares to the immune response
induced by vaccination against CP conjugates alone, groups of cynomolgus macaques
were vaccinated with either the bivalent CP vaccine (CP5-CRM197 or CP8-CRM197) or the
SA4Ag vaccine and the induced immune responses were characterized. Functional
antibody responses, quantities of memory B and T cells, and levels of cytokine pro-
duction from preimmunization and postimmunization T cells and bulk peripheral blood
mononuclear cells (PBMCs) were measured. Our results demonstrate that both the
capsular polysaccharide antigens and the protein antigens are immunogenic and that
both vaccines induced memory B-cell and functional antibody responses. In contrast,
neither of the vaccines induced increases in the levels of circulating activated T cells
(either TH1 or TH17), though both vaccines may have promoted recruitment of T
follicular helper cells to lymph nodes. Collectively, these data suggest that the response
to these vaccines could be driven by B cells and antibodies and that the inclusion of the
surface protein antigens does not negatively affect the anti-CP immune response and
does not induce a strong effector T cell response.
RESULTS
Analysis of innate immune responses induced by the CP5-CRM197 and CP8-
CRM197 or MntC and ClfA antigens. Adaptive immune responses that confer protec-
tion following vaccination are ultimately regulated by the initial cytokines that are
released when speciﬁc ligands are sensed by innate pattern recognition receptors (39).
We sought to determine whether or not the innate cytokine responses induced by the
MntC and ClfA antigens were distinct from those induced by the CP5-CRM197 and
CP8-CRM197 antigens. PBMCs from unvaccinated macaques were cultured in the ab-
sence of antigen or in the presence of ClfA and MntC or of CP5-CRM197 and CP8-CRM197
antigens. The concentrations of 29 cytokines were measured in the supernatants after
incubation. Partial least-squares discrimination analysis (PLS-DA) was applied to deter-
mine if the pairs of antigens elicited distinct cytokine responses and what cytokines
distinguish these responses from one another. This analysis revealed that the macaque
cells from each antigen stimulation condition clustered into distinct groups, distin-
guishable by the cytokines that they produced (Fig. 1A). Stimulation with MntC and
ClfA or with both CP5-CRM197 and CP8-CRM197 induced secretion of the cytokines IL-2,
IL-12, epidermal growth factor (EGF), and migration inhibition factor (MIF) (Fig. 1B and
C). Stimulation with CP5-CRM197 and CP8-CRM197 also induced secretion of CCL5. In
contrast, stimulation with MntC and ClfA did not induce secretion of CCL5. The two
antigen pairs differed in the amounts of MIF and EGF that they induced. The ClfA and
MntC antigen pairs also induced greater IFN- production than the CP5-CRM197 and
CP8-CRM197 antigen pairs, although, correcting for the multiple comparisons being
made, this trend was not statistically signiﬁcant. Collectively, these data demonstrate
that both antigen pairs (antigens CP5 and CP8 and antigens ClfA and MntC) are
immunogenic and capable of eliciting cytokine responses but that the cytokine re-
sponses that they elicit are distinct from one another.
Analysis of memory B-cell responses induced by bivalent vaccine treatment or
SA4Ag vaccination.Memory B cells represent one component of the adaptive immune
system that can confer vaccine-induced protection, and the vast majority of vaccines
currently in use are thought to elicit B-cell responses (40). Therefore, we next compared
the frequencies of memory B cells, and the relative binding afﬁnities of the antibodies
secreted by them, following bivalent vaccine treatment or SA4Ag vaccination. The
kinetics of the memory B-cell response throughout the vaccination regimen was
examined by ﬂow cytometry, measuring expression of receptor CD27, which is upregu-
lated on memory B cells, and receptor CD23, which is expressed on naive B cells (41).
Analysis of these markers revealed three populations of B cells (CD23 CD27, CD23
CD27, and CD23 CD27). Of these, only the level of the CD23 CD27 population
was found to have increased at day 70 following vaccination (Fig. 2A; see also Fig. S1 in
Comparative Analysis of Staphylococcal Vaccination
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FIG 1 Analysis of innate antigen-induced cytokine responses. Cryopreserved PBMCs were cultured with no antigen, CP5
and CP8, or ClFA and MntC antigen. After incubation for 48 h, the concentrations of 29 cytokines in the supernatants were
measured by Luminex analysis. Concentrations of all 18 cytokines with detectable signal were inputted into a partial
least-squares discriminant analysis (PLS-DA) algorithm in order to identify key cytokines corresponding to each antigen
stimulation condition. This algorithm outputted the data in a principal-component space, where each component
represents an axis of maximal variance in the data and separation between stimulation conditions. (A) Each data point,
plotted in the PLS-DA principal-component space, represents all 18 cytokine concentrations from an individual naive
macaque under a speciﬁc antigen stimulation condition. The macaques maintained within each antigen stimulation
condition clustered together, suggesting a consistent set of cytokines induced across all macaque PBMCs within a speciﬁc
stimulation condition. (B) The loadings for each principal component indicate which cytokines corresponded to each
antigen stimulation condition. For example, based on the loadings of principal component 1, the CP5 and CP8 antigens
stimulated increased expression of MIF, CCL5, and IL-12. (C) Observed concentrations of individual cytokines are shown.
Each data point represents an individual naive macaque under a speciﬁc antigen stimulation condition. The red lines
(Continued on next page)
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the supplemental material). Vaccination with either the SA4Ag vaccine or the bivalent
vaccine induced increases in the levels of memory B cells, which peaked at the end of
the vaccination regimen. These data suggest that inoculation with either the SA4Ag
vaccine or the bivalent vaccine elicits memory B-cell responses.
Another important aspect of the B-cell response to assess is antigen speciﬁcity. To
compare the antigen-speciﬁc memory B-cell responses elicited by each vaccine, PBMCs
collected before vaccination and at day 70 postvaccination were stimulated to induce
antibody secretion. The levels of secretion of antibodies and their speciﬁcities were
then measured using microengraving. After stimulation, cells were deposited into an
array of subnanoliter wells (50 m by 50 m by 100 m); the antibodies secreted by
individual B cells within each well were then captured on a glass slide and probed with
ﬂuorescently labeled antigens and detection antibodies (42). Using this technique, B
cells that secreted antibodies could be clearly identiﬁed, along with the speciﬁcity of
the antibodies for each vaccine component (Fig. 2B). Using this approach, we observed
that both bivalent CP and SA4Ag induced increases in the frequencies of CP5- and
CP8-speciﬁc B cells and that SA4Ag induced increases in the frequencies of ClFA- and
MntC-speciﬁc B cells in the majority of macaques examined. Comparing the frequencies
of CP5- and CP8-speciﬁc memory B cells from prevaccination and 70 days postvacci-
nation revealed that the bivalent CP and SA4Ag vaccines elicited similar increases in the
frequencies of antigen-speciﬁc memory B cells (Fig. 2C).
Analysis of T-cell responses induced by bivalent vaccine treatment or SA4Ag
vaccination. In addition to memory B cells, T cells represent another compartment of
the adaptive immune system that may be involved in protection following vaccination.
T-cell-mediated immunity has been implicated in resistance to S. aureus (3–5) and has
also been negatively linked to vaccine safety (43). We used several approaches to
measure the vaccine-induced T cell responses. First, T cells taken from macaques were
analyzed ex vivo by ﬂow cytometry for vaccine-induced changes in the expression of
activation-associated molecules. Speciﬁcally, T cells were examined for expression of
surface molecules CD69, PD-1, and HLA-DR (which are upregulated on recently acti-
vated CD4 T cells) (44, 45); surface molecule CD45RA (which is downregulated on
antigen-experienced CD4 T cells) (46); and intracellular protein Ki-67 (which is asso-
ciated with cellular proliferation) (47). Flow cytometric analysis revealed no changes in
the expression of any of these molecules (Fig. 3A; see also Fig. S2A) following bivalent
CP or SA4Ag vaccination, arguing against a prominent role for circulating T-cell
populations in vaccine-induced immunity.
To further assess vaccine-induced immune responses, intracellular cytokine staining
(ICS) was performed to determine whether bivalent CP or SA4Ag vaccination increased
cytokine production. Expression levels of tumor necrosis alpha (TNF-), IFN-, and IL-17
were measured; all of these cytokines have been implicated in immunity to S. aureus (5,
6, 18, 48, 49). Expression of IL-4 was also measured, since this cytokine can promote
B-cell responses (16). After stimulating cryopreserved PBMCs from macaques with
phorbol myristate acetate (PMA) and ionomycin to induce activation, no vaccine-
induced increases in cytokine production were observed (Fig. 3B; see also Fig. S2B). In
a further effort to detect antigen-speciﬁc cytokine responses, cryopreserved PBMCs
from multiple pre- and postvaccination time points were cultured with the vaccine
components, and the concentrations of an array of 29 cytokines (including IL-4, IL-17,
TNF-, and IFN-) were then measured. While treatment of the PBMCs with antigens
induced increases in the secretion of a number of cytokines regardless of the time point
postvaccination, no evidence of vaccine-induced increases in cytokine secretion was
apparent using this method (Fig. 4; see also Fig. S3). Collectively, these results suggest
that neither the bivalent CP nor SA4Ag induced signiﬁcant activation of circulating T
cells.
FIG 1 Legend (Continued)
indicate the limit of detection (LOD) for each cytokine; measurements at or below the LOD were excluded from statistical
analysis. P values were calculated using a Mann-Whitney U test. ns, not signiﬁcant.
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Recent studies have demonstrated that T follicular helper cells (TFH), a cellular
population specialized in promoting B-cell responses, can be detected in circulation
and that they bear a CD4 CD45RA CXCR3 CXCR5 PD-1HI TIGITHI c-mafHI pheno-
type (50). Identiﬁcation of these cells in macaques is complicated by the low levels of
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FIG 2 Memory B-cell responses to bivalent and SA4Ag vaccination. (A and B) Memory B-cell responses measured by ﬂow
cytometry. Cryopreserved PBMCs from vaccinated and unvaccinated macaques were thawed and stained with antibodies
to identify activated B cells. Representative ﬂow cytometry plots show the CD27 and CD23 expression of B cells (A). Flow
plots are gated on singlet, live, CD20 CD3 CD56 CD16 cells. Kinetics of the memory B-cell response in each
vaccination group are shown. Changes in CD27 expression were calculated by subtracting the percentage of B cells that
were positive for CD27 at day 0 from the percentage of B cells that were positive for CD27 at each time point. Gray arrows
represent the time points at which macaques were vaccinated. When samples from day 0 for a given macaque were
unavailable, other time points were normalized to day 7 and the value representing the change in CD27 at day 7
(which was by deﬁnition 0) was excluded. All macaques were analyzed at each time point except when insufﬁcient sample
was available. A paired t test was used to assess signiﬁcance of CD27 B cell frequencies at each time point compared to
day 0. A single asterisk (*) refers to an adjusted P value of 0.05 (Bonferroni correction). The n values for each group at
each time point are as follows: bivalent, n  9, 10, 4, 9, 9, 10, 8, 9, 10, and 9; SA4Ag, n  7, 10, 8, 9, 9, 10, 5, 9, 7, and 7;
control, n  9, 6, 8, 8, 10, 9, 9, 8, 5, and 7. Means  standard errors of the means (SEM) are shown. (B) Sample images
showing microengraving signals. (C) Frequencies of antigen-speciﬁc B cells prevaccination and at day 70 postvaccination,
determined by microengraving; “Biv” refers to bivalent vaccine, and “Tet” refers to tetravalent or SA4Ag vaccine. A
Wilcoxon rank sum test was used to assess the signiﬁcance of the results of comparisons between the prevaccination and
postvaccination frequencies. A single asterisk (*) indicates signiﬁcance at alpha  0.05. The n values for each group for
each antigen are as follows: bivalent, n  9 and 10 (CP5 and CP8); SA4Ag, n  9, 10, 5, and 5 (CP5, CP8, Clfa, and MntC).
Insufﬁcient numbers were present to perform the test in the cases of Clfa and MntC.
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FIG 3 Examination of T-cell activation status and cytokine production before and after vaccination. (A)
Expression of activationmarkers on T cells at various time points following vaccination. Expression of CD45RA,
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detectable CXCR5 expressed on macaque T cells (51). However, a population of CD4
CD45RA CXCR3 PD-1HI TIGIT c-maf cells could be detected in the macaque’s
circulation. Vaccination with either the SA4Ag or bivalent CP vaccine (but not control
buffer) induced signiﬁcant decreases in this population (Fig. 5A and B). No signiﬁcant
differences were apparent when the frequencies of these cells were compared between
FIG 3 Legend (Continued)
Ki-67, CD69, PD-1, and HLA-DR on the surface of T cells was examined. Representative ﬂow cytometry plots
are shown. Flow plots are gated on singlet, live, CD3 CD4 T cells. Changes in expression of each activation
marker represent the difference between the percentage of T cells positive at each time point and the
percentage at day 0. When samples from day 0 for a given macaque were unavailable, other time points were
normalized to day7 and the value representing the change in CD27 at day7 (which was by deﬁnition 0)
was excluded. The data shown represent an analysis of half of the population of macaques used for this study.
PBMCs from the other half of the population of macaques were stained with a slightly different panel, and
these data are shown in Fig. S2. Macaques were excluded only when insufﬁcient sample was available.
N values for each time point are as follows: bivalent, n  5, 5, 1, 5, 5, 5, 4, 5, 5, and 5; SA4Ag, n  4, 4, 3, 4,
4, 5, 2, 3, 2, and 3. Means  SEM are shown. FMO, ﬂuorescence minus one. (B) Production of cytokines from
bivalent and SA4Ag-vaccinated macaques at various time points, measured by intracellular cytokine staining.
PBMCs were stimulated for 4 h with PMA and ionomycin at a concentration of 1 g/ml and BD GolgiStop
according to the manufacturer’s instructions. Representative ﬂow cytometry plots are shown. Plots are gated
on singlet, live, CD3 CD4 T cells. Changes in expression of each activation marker represent the difference
between the percentage of T cells positive at each time point and the percentage at day 0. When samples
from day 0 for a givenmacaque were unavailable, other time points were normalized to day7 and the value
representing the change in CD27 at day 7 (which was by deﬁnition 0) was excluded. The data shown
represent an analysis of half of the population of macaques used for this study. PBMCs from the other half of
the population of macaques were stimulated in an earlier experiment with a lower concentration of PMA and
ionomycin (0.1 g/ml), and these data are shown in Fig. S2. Macaques were excluded only when insufﬁcient
sample was available. N values for each time point are as follows: bivalent, n  5, 5, 2, 5, 5, 5, 4, 3, 5, and 5;
SA4Ag; n  5, 5, 3, 3, 4, 5, 2, 4, 2, and 3. Means  SEM are shown.
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FIG 4 Cytokine production resulting from antigen stimulation. Cryopreserved PBMCs from each vaccine group, at each time point,
were thawed, rested overnight, and cultured at a concentration of 500,000 cells/well in 90 l of AIM-V media per well. Cells were
stimulated with 8 g/ml of MntC and ClfA or CP5 and CP8 antigens. Supernatants were harvested and examined for cytokine content
after 48 h of stimulation. Limits of detection for each cytokine (as reported by the manufacturer) are depicted with the dashed line.
Points falling below the standard curve were excluded. Other samples were excluded only when insufﬁcient sample was present.
N values for each time point are as follows: bivalent, no antigen, n  10, 10, 10, and 9; SA4Ag, no antigen, n  10, 10, 10, and 10;
bivalent, CP5 and CP8 stimulation, n  10, 10, 10, and 10; SA4Ag, CP5 and CP8 stimulation, n  10, 10, 10, and 10; bivalent, MntC
and ClfA stimulation, n  10, 9, 10, and 4; SA4Ag, MntC and ClfA stimulation, n  10, 9, 9, and 7.
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the bivalent and SA4Ag vaccine groups. Importantly, when this gating strategy was
applied to human PBMCs, a majority of cells within the CD4 CD45RA CXCR3 PD-1HI
TIGIT c-maf population were found to be CXCR5 (i.e., were circulating TFH cells)
(Fig. 5C). These results are therefore consistent with a model in which vaccination
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FIG 5 Vaccination induces a decrease in CD4 CD45RA CXCR3 PD-1Hi TIGIT c-maf T cells. (A and
B) Cryopreserved T cells from days 0 and 70 post-initial vaccination were thawed and rested overnight.
Expression of markers for T follicular helper cells was measured on each. A representative gating strategy
to identify CD4 CD45RA CXCR3 PD-1HI TIGIT c-maf T cells is shown (A), and the frequencies of
these cells as a percentage of the total CD4 T-cell population were quantiﬁed (B). Ctrl, control or vaccine
buffer; Biv, bivalent vaccine; Tet, tetravalent vaccine. (C) A representative gating strategy to identify
circulating TFH cells in a human subject is shown.
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induces a decrease in the circulating TFH cell population, possibly due to the recruit-
ment of circulating TFH cells to lymph nodes.
Effects of vaccination on humoral immune responses. To measure the functional
properties of the antibody responses induced by vaccination with the bivalent and
SA4Ag macaques, sera from each macaque were collected at multiple time points and
analyzed in two ways: the ability of the sera to opsonize S. aureus for phagocytosis by
neutrophils in vitro was determined using an opsonophagocytic assay (OPA), and the
ability of antibodies from the sera to prevent binding of ﬂuorescently labeled mono-
clonal antibodies (Abs) to the antigenic vaccine components was determined using a
competitive Luminex immunoassay (cLIA) (52).
The OPA revealed that vaccination with either the bivalent CP or SA4Ag induced a
rapid increase in the ability to opsonize both CP5-expressing and CP8-expressing
isolates of S. aureus. This outcome was apparent in comparisons of sera of macaques
from day 0 to sera from day 14 post-initial vaccination and in comparisons of vacci-
nated macaques to nonvaccinated control groups (Fig. 6A; see also Fig. S4A). Both the
percentage of macaques capable of opsonizing S. aureus and the titer at which
opsonization occurred were signiﬁcantly increased by vaccination with either the
bivalent CP or SA4Ag. The increased ability to opsonize bacteria was sustained through-
out the vaccination regimen in both bivalent CP-immunized and SA4Ag-immunized
animals. No signiﬁcant differences were apparent between the bivalent CP- and
SA4Ag-vaccinated animals in their ability to opsonize S. aureus or in the titers at which
opsonization occurred. Collectively, these results suggest that both the bivalent CP and
SA4Ag vaccines induce humoral immune responses that are comparable with respect
to their ability to opsonize S. aureus.
Humoral immune responses to vaccination were also assessed using cLIA, which
measures the ability of antibodies in the sera to inhibit the binding of ﬂuorescently
labeled monoclonal antibodies speciﬁc for the antigenic components of the vaccine
(53). Using this approach, increases in the levels of CP5- and CP8-speciﬁc antibodies
were apparent in both bivalent CP- and SA4Ag-immunized macaques following vacci-
nation, as indicated by signiﬁcant increases in the percentages of macaques whose sera
were able to inhibit the binding of monoclonal antibodies to their cognate antigen and
in the titers at which binding was inhibited (Fig. 6B; see also Fig. S4B). The CP5- and
CP8-speciﬁc antibody responses induced by the SA4Ag and bivalent CP vaccines were
sustained throughout the vaccination regimen. When the responses induced by the
SA4Ag vaccine and bivalent CP vaccine were compared to one another using a 2-way
analysis of variance (ANOVA), the anti-CP5 responses were found to be signiﬁcantly
different from one another. Comparisons between the SA4Ag- and bivalent CP-
vaccinated macaques at each individual time point, however, revealed no signiﬁcant
differences (once corrections were made for performing multiple comparisons). No
differences in the vaccine-induced anti-CP8 response were apparent between the
bivalent CP- and SA4Ag-immunized macaques, as measured by the cLIA. The cLIA also
revealed that antibody responses against ClfA and MntC were induced by vaccination
with the SA4Ag vaccine but not by vaccination with the bivalent CP vaccine, as
expected. The humoral responses against these protein antigens generally exhibited a
kinetics different from that of the responses against the polysaccharide antigens and
were slower to develop. Additionally, MntC antibody responses were difﬁcult to detect
by cLIA (although this may be a species-speciﬁc phenomenon, as cLIA-based responses
to MntC are generally robust in humans [53]). Collectively, these results demonstrate
that both the SA4Ag and bivalent CP vaccines induce functional humoral immune
responses against all the antigenic components of each respective vaccine and show
no evidence that the inclusion of the protein surface antigens negatively affects the
anti-CP humoral response.
DISCUSSION
Several previous efforts to develop vaccines for S. aureus have been unsuccessful
(22). These approaches have targeted single antigens or targeted combinations of CPs
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FIG 6 Functional analysis of antibodies in the sera induced by the bivalent vaccine-treated or SA4Ag vaccines. Sera were
harvested from bivalent vaccine-treated, SA4Ag-vaccinated, or control buffer-vaccinated macaques at the indicated time
points. (A) Analysis of opsonophagocytic activity. Sera were diluted and incubated with CP5-expressing or CP8-expressing
isolates of S. aureus and human polymorphonuclear leukocytes overnight. The amount of bacteria present in each culture
was quantiﬁed the following morning. Titers at which 50% of the bacteria were killed are reported. Titers represent the
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(54). Given that expression of individual antigens is dynamic during infection, use of a
multivalent vaccine targeting both CPs and surface antigens may be the most effective
vaccination strategy (26). This strategy, however, raises the following question: how
would inclusion of additional antigens affect the anti-CP immune response?
The studies performed here interrogated the effect that inclusion of additional
surface antigens (ClfA and MntC) has on the immune responses against CPs. We
observed no evidence that the anti-CP immune response was inhibited by the addition
of the protein surface antigens. Indeed, the macaques exhibited similar frequencies of
CP-speciﬁc memory B cells regardless of whether they were vaccinated with CP5 and
CP8 alone or in combination with MntC and ClfA. Similarly, antibody responses (mea-
sured by cLIA or OPA) were not impaired by the addition of the ClfA and MntC antigens.
Clinical data have conﬁrmed that when MntC and ClfA are included in a multivalent
vaccine, robust immune responses are observed (53, 55). Our data therefore suggest
that the use of multivalent vaccines may be a promising strategy to prevent infection
with S. aureus.
The results of this study also demonstrate that antigens ClfA and MntC and antigens
CP5-CRM197 and CP8-CRM197 are antigen pairs capable of eliciting cytokine production
from naive PBMCs and that both also induced antibody and memory B-cell responses
following vaccination. These results are consistent with previous studies demonstrating
the immunogenicity of CP5-CRM197, CP8-CRM197, MntC, and ClfA in healthy human
subjects (53, 56). Interestingly, the antigen pairs induced distinctly different cytokine
signatures in naive PBMCs, with CP5-CRM197 and CP8-CRM197 stimulation causing very
high levels of MIF and CCL5 and with ClfA and MntC stimulation leading to elevated
levels of EGF, hepatocyte growth factor (HGF), IFN-, and IL-12. These results suggest
that the two antigen pairs have immune stimulatory effects that are distinct, which
might play a subtle role in shaping the vaccine-induced immune response. Overall, the
inherent immunogenicity of these antigens is important, as the SA4Ag vaccine cur-
rently in development contains no adjuvant.
It is presently unclear whether inducing TH17 or TH1 responses is a prudent strategy
to prevent infection with extracellular pathogens. While local TH17 responses promote
neutrophil migration to the site of infection, TH17 cells also can promote autoimmune
responses (7). Likewise, while some researchers have described a protective role for TH1
responses in S. aureus infection following exposure to live S. aureus (20), a recent report
has shown that induction of a TH1 response after vaccination with S. aureus may be
deleterious (43). Our results found no evidence that vaccination with either the bivalent
CP or SA4Ag vaccines induces TH1 or TH17 immune responses, suggesting that a similar
result may also be observed in the clinic. As the majority of vaccines currently in use are
thought to mediate protection primarily through antibody responses (40), it is reason-
able to speculate that these memory TH1 or TH17 cell responses may not be necessary
FIG 6 Legend (Continued)
reciprocal of the serum dilution. Geometric mean titers 95% conﬁdence intervals are shown. Values which fell below the
limit of detection (where no detectable opsonization occurred) have been entered as 50. The geometric mean titer at
which 50% of the bacteria were killed following vaccination (at day 14) is compared to the geometric mean titer at which
50% of the bacteria were killed prior to vaccination at day 0 within each group using a Wilcoxon signed-rank test. The
geometric mean titer at which 50% of the bacteria were killed at day 14 in each group was compared to the geometric
mean titer at which 50% of the bacteria at day 14 were killed in each other group using a Mann-Whitney U test (values
not shown). (B) Antigen-binding ability of antibodies in sera measured by competitive Luminex immunoassay. Concen-
trations of sera (expressed in units per milliliter) at which 50% inhibition of the monoclonal antibody to its cognate vaccine
component antigen occurred are displayed. Concentrations are displayed as geometric means 95% conﬁdence intervals.
To improve image clarity, the conﬁdence intervals for the control buffer-vaccinated group were excluded. For visualization
purposes, any conditions where all donors had values below the limit of detection (LOD) are plotted at half of the lower
limit of quantitation (LLOQ) for visualization purposes, and the LLOQ is shown as a dashed line. When a sufﬁcient number
of macaques in each group had sera which detectably inhibited binding activity at day 0, the concentrations at which
inhibition of binding occurred at day 0 and following vaccination were compared using a Wilcoxon matched-pair rank test.
When a sufﬁcient number of macaques in the control buffer-vaccinated group had sera which detectably inhibited binding
activity following vaccination, the concentration at which binding was inhibited in this group was compared to the
concentration at which it was inhibited in the bivalent vaccine-treated group or the SA4Ag-vaccinated group using a
Mann-Whitney U test (values not shown).
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for protective immunity against S. aureus and could potentially be dangerous. Eliciting
B-cell responses without TH1 or TH17 cells may therefore be ideal, as this strategy would
mitigate concerns about the potential of vaccines to increase the risk for autoimmune
disease and enhanced systemic inﬂammatory responses upon infection. Regardless, a
greater understanding of the extent to which TH17 cells that are not self-reactive
contribute to autoimmunity may help to inform future vaccine design.
Previous studies have measured circulating TFH cells and identiﬁed correlations
between the frequencies of these cells and various phenotypes, such as the presence
of broadly neutralizing antibodies in HIV patients (50, 57). Our studies identiﬁed a
decrease in CD4 CD45RA CXCR3 PD-1HI TIGIT c-maf levels induced by vaccina-
tion, and experiments using human PBMCs demonstrated that this population contains
circulating TFH cells. Our results, however, identiﬁed no correlations between the
decreases in this cell population and other parameters of the immune response, such
as the increase in the frequency of memory B cells induced by vaccination or in the
antibody responses, as measured by cLIA or OPA (data not shown). Regardless, our
results implicate TFH involvement in the vaccine-induced immune response; this ﬁnd-
ing is consistent with current models in which TFH cells are thought to be necessary for
class-switching and memory B cell development. Analyzing this population with
greater resolution should be possible in human subjects, as CXCR5 is more easily
detected on human T cells than on macaque T cells (51). Studies in human subjects may
therefore reveal an important role for this population in the context of vaccine-induced
immunity to S. aureus.
MATERIALS AND METHODS
Animals and immunization. All animal protocols employed in this study met the established Pﬁzer
Institutional Animal Care and Use Committee guidelines, and all animal work was conducted in an
AALAC-accredited facility. Thirty cynomolgus macaques (Macaca fascicularis) were vaccinated intramus-
cularly with the bivalent vaccine (10 g CP5-CRM197 and 10 g CP8-CRM197), the SA4Ag vaccine (10 g
CP5-CRM197, 10 g CP8-CRM197, 20 g ClfA, and 20 g MntC), or control vaccine buffer without adjuvant
(n  10) on days 0, 29, and 56 of the study. Blood was drawn 7, 0, 7, 14, 29, 35, 43, 56, 63, and 70 days
post-initial vaccination. Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood and
stored at 200°C.
Cell preparation. Cells were thawed by brieﬂy incubating them in a 37°C water bath and were added
dropwise to room temperature AIM-V media (Thermo Fisher) containing 20 units/ml Benzonase (Nova-
gen). Cells were washed extensively and rested overnight at 37°C in AIM-V media supplemented with
10% fetal bovine serum (FBS) (Gibco) for ﬂow cytometry and Luminex experiments or were stimulated
for 5 days in media (0.25  106 cells/ml) supplemented with 10% FCS, 2.5 g/ml R848 (InvivoGen), and
1,000 U/ml IL-2 (PeproTech) for microengraving experiments (58).
Flow cytometry. The following antibodies were used for ﬂow cytometric analysis: brilliant UV (BUV)
737 anti-human IgG antibody (BD; clone G18-145), BUV395 mouse anti-human IgM antibody (BD; clone
G20-127), polyclonal goat anti-human IgA antibody (Jackson; product number 109-005-149), phycoeryth-
rin (PE) anti-macaque CD38 antibody (Nonhuman Primate Reagent Resource; clone OKT10), brilliant
violet (BV) 605 anti-human CD20 antibody (BioLegend; clone 2H7), BV785 anti-human CD27 antibody
(BioLegend; clone O323), Alexa Fluor (AF) 488 anti-human CD16 antibody (BioLegend; clone 3G8), AF488
anti-human CD56 antibody (BioLegend; clone MEM-188), AF488 anti-human CD3 antibody (BD; clone
SP34), PE-Cy7 CD23 antibody (BD; clone M-L233), BV711 anti-human CD27 antibody (BioLegend; clone
O323), BUV395 anti-human CD3 antibody (BD; clone 563563), allophycocyanin-H7 (APC-H7) anti-human
CD4 antibody (BD; clone L200), ﬂuorescein isothiocyanate (FITC) anti-human CD45RA antibody (Miltenyi;
clone T6D11), BV785 anti-human PD-1 antibody (BioLegend; clone EH12.2H7), BV605 anti-human CXCR3
antibody (BD clone 1C6 and BioLegend clone GO25H7), PerCP-Cy5.5 anti-human CD69 antibody (Bio-
Legend; clone fn50), BUV737 HLA-DR antibody (BioLegend; clone L243), APC anti-human TIGIT antibody
(EBioscience; clone MBSA43), Percp-Cy5.5 anti-Ki-67 antibody (BD; clone B56), BUV395 anti-human IFN-
antibody (BD; clone B27), PE anti-human IL-17 antibody (BD; clone SCPL1362), APC anti-human IL-4
antibody (BioLegend; clone 8D4-8), PE-Cy7 anti-human TNF- antibody (BioLegend; clone MAb11), and
PE anti-human/mouse c-maf antibody (EBioscience; clone sym0F1).
Human gamma globulin (Jackson) or fuman Fc block (BD) was used to inhibit binding to Fc receptors.
The polyclonal anti-human IgA antibody was conjugated to PE-Cy7 using a conjugation kit (Abcam, Inc.;
product number ab102903). A Zombie Violet ﬁxable viability kit (BioLegend; product number 423114)
was used to discriminate live and dead cells. Cells were stained for 25 min at 4°C for all extracellular
surface stains. Staining was performed in Brilliant Stain buffer (BD). After staining, cells were washed with
ﬂuorescence-activated cell sorter (FACS) buffer (1 phosphate-buffered saline [PBS] supplemented with
0.2% bovine serum albumin [BSA; Sigma-Aldrich] and 1 mM EDTA [Promega]). Cells were ﬁxed by
incubation in 2% paraformaldehyde (PFA) (EMS) for 10 min. Cells were suspended in FACS buffer and
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analyzed using an LSR Fortessa ﬂow cytometer. Data analysis was performed using FlowJo software
(TreeStar) and Prism (GraphPad).
Microengraving. Microengraving protocols were performed following previously described meth-
ods (59). For microengraving analysis of macaque PBMCs, 25 g/ml of polyclonal anti-human IgA plus
IgG plus IgM (Jackson ImmunoResearch) and 25 g/ml anti-rabbit IgG (Jackson ImmunoResearch) diluted
in borate buffer were pipetted onto poly-lysine-coated slides, sealed with a coverslip, and incubated
overnight in a humidity chamber at 4°C. Arrays comprising ~105 wells (50 m by 50 m by 100 m) were
prepared as previously described (60). Following stimulation to induce antibody production, cells were
enriched for antibody-secreting cells using negative magnetic selection (EasySep human B cell enrich-
ment kit; StemCell Technologies) and were pipetted onto the wells at a density of ~1 cell per well,
allowed to settle, sealed with the anti-IgG-coated slides, and incubated for 1 h at 37°C. Rabbit serum
(Sigma-Aldrich) was added to the cells at a concentration of 1:8,000. Slides were subsequently probed
with 5 g/ml of AF488-labeled anti-human IgG antibody (BD; clone G18-145), AF700-labeled goat-anti
rabbit antibody (Life Technologies, Inc.), and ﬂuorescently labeled antigens (AF555-labeled CP5-HSA
conjugate with AF647-labeled CP8-HSA conjugate or AF555-labeled MntC with AF647-labeled ClfA). All
antigens were obtained from Pﬁzer and used at a concentration of 50 g/ml. All antigens were
conjugated to dyes using sodium bicarbonate before processing through ﬂuorescent dye-removal
columns (Pierce Biotechnology) was performed. Alexa Fluor ﬂuorophores were obtained from Life
Technologies, Inc.
Slides were washed and scanned using a GenePix 4400A microarray scanner (Molecular Devices). The
images generated were analyzed using Crossword software (61) in addition to software developed
in-house (T. M. Gierahn, unpublished data). Positive ﬂuorescent events were identiﬁed based on the
signal-to-noise ratio and average pixel intensity and were conﬁrmed by visual inspection. Wells contain-
ing single cells were analyzed to determine the percentage of cells that secreted immunoglobulin. This
frequency was multiplied by the total number of cells on each nanowell array (including wells that
contained more than 1 cell) to determine the number of cells that secreted immunoglobulin. Numbers
of antigen-speciﬁc spots were divided by the total calculated numbers of immunoglobulin-secreting cells
on each array to determine the frequencies of antigen-speciﬁc cells. Due to the low frequencies of
antigen-speciﬁc cells (generally less than 0.1%), it was assumed that any wells containing multiple cells
held only 1 cell speciﬁc for each antigen. CRM197-speciﬁc B cells were excluded from analysis and
identiﬁed as events that stained positive with both CP5-CRM197 and CP8-CRM197.
Fluorescence microscopy. Microengraving data were supplemented with images of the nanowells
to determine the occupancy of each well and the viability of each cell. Following microengraving, cells
(within the nanowell arrays) were stained with the ﬂuorescent viability dye calcein AM (Invitrogen) at
0.25 g/ml. Images were collected using an epiﬂuorescence microscope (Zeiss) and software developed
in-house (D. Loginov, unpublished data).
Antigen stimulation and cytokine measurement by Luminex analysis. For antigen stimulation
experiments, macaque PBMCs were thawed, rested overnight, and plated at a concentration of
500,000 cells/well. Cells were stimulated with 8 g/ml of each antigen in AIM-V media for 48 h.
Supernatants were harvested, and the concentrations of the following cytokines were measured:
granulocyte-macrophage colony-stimulating factor (GM-CSF), TNF-, IL-1, IL-4, IL-6, MIG, vascular
endothelial growth factor receptor (VEGF), HGF, EGF, IL-8, IL-17, MIP-1, IL-12, IL-10, ﬁbroblast growth
factor-Basic (FGF-Basic), IFN-, granulocyte colony-stimulating factor (G-CSF), monocyte chemoattractant
protein 1 (MCP-1), IL-15, IP-10, MIP-1, eotaxin, RANTES, IL-1RA, I-TAC, MIF, MDC, IL-5, and IL-2. Cytokines
were measured using a cytokine Monkey Magnetic 29-plex panel for a Luminex Platform kit (Thermo
Fisher) following the manufacturer’s instructions.
Assessment of antigen-speciﬁc antibody responses to vaccination. (i) Opsonophagocytic assay
(OPA). Serological responses to capsular polysaccharides CP5 and CP8 were measured by opsonophago-
cytic assay (OPA) as previously described (15). Brieﬂy, serial dilutions of heat-inactivated immune sera
were mixed with either a CP5- or CP8-expressing clinical isolate of S. aureus and allowed to opsonize the
bacteria. The reaction mixtures were then mixed with baby rabbit complement (Pel-Freez) and
neutrophil-like HL-60 cells. An OPA antibody titer was deﬁned as the reciprocal of the highest serum
dilution resulting in a 50% reduction of the number of bacterial colonies after incubation for 60 min at
37°C compared to the serum-free background control. Samples without detectable activity at the lowest
serum dilution of 100 were assigned OPA titer values of 50.
(ii) Competitive Luminex immunoassay (cLIA). Competitive immunoassays were used to quantify
antigen-speciﬁc binding antibodies elicited by the investigational vaccine. The assays monitor the ability
of each vaccine component to elicit antibodies that can compete with the binding of antigen-speciﬁc
monoclonal antibodies (MAbs) that have shown functional activity either in vitro or in vivo. This approach
provides insight into the function and protectiveness of the antigen-speciﬁc antibodies. The ClfA MAb
prevents binding of live S. aureus to ﬁbrinogen (36), while the MntC MAb inhibits manganese uptake (62).
The MAbs used for the CPs facilitated killing of S. aureus as measured by OPA. The cLIA is based on the
Luminex MagPlex xMAP technology platform. Spectrally distinct microspheres are coated individually
with each of the following antigens, resulting in a mixture of distinct microspheres: CP5, CP8, recombi-
nant ClfA (rmClfA), and recombinant P305A (rP305A). Antigen-coated microspheres are incubated
overnight with appropriately diluted serum samples. A mixture of PE-labeled CP5-, CP8-, rmClfA-, and
rP305A-speciﬁc mouse monoclonal antibodies (MAbs) is then added to the microsphere/serum mixture,
and after incubation, the unbound components are washed off. The presence of the ﬂuorescent protein
coupled to the monoclonal antibodies allows measurement of the antibody bound to the antigen-coated
microspheres by the Bio-Plex reader. Signals expressed as median ﬂuorescence intensities (MFIs) were
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generated, and the data were converted to units per milliliter using four-parameter logistic (4PL) curves
from the reference standard serum, with assigned antibody titers expressed in units per milliliter. This is
a competitive assay, and the magnitude of the ﬂuorescent PE signal is inversely proportional to the
amount of antigen-speciﬁc antibodies in the sample.
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